FOSTAMATINIB Drug Patent Profile
✉ Email this page to a colleague
When do Fostamatinib patents expire, and what generic alternatives are available?
Fostamatinib is a drug marketed by Annora Pharma and is included in one NDA.
The generic ingredient in FOSTAMATINIB is fostamatinib disodium. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the fostamatinib disodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fostamatinib
A generic version of FOSTAMATINIB was approved as fostamatinib disodium by ANNORA PHARMA on June 17th, 2026.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FOSTAMATINIB?
- What are the global sales for FOSTAMATINIB?
- What is Average Wholesale Price for FOSTAMATINIB?
Summary for FOSTAMATINIB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | FOSTAMATINIB at DailyMed |
US Patents and Regulatory Information for FOSTAMATINIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | FOSTAMATINIB DISODIUM | fostamatinib disodium | TABLET;ORAL | 217329-001 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Annora Pharma | FOSTAMATINIB DISODIUM | fostamatinib disodium | TABLET;ORAL | 217329-002 | Jun 17, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
